Direct Healthcare Professional Communication (DHPC) on oral retinoids (acitretin, alitretinoin and lsotretinoin): Reminder of existing restrictions to prevent exposure during pregnancy
2024.05.02
Active substance: acitretin, alitretinoin, isotretinoin
The marketing authorisation holders of medicinal products containing acitretin, alitretinoin and isotretinoin, in agreement with the Federal Institute for Drugs and Medical Devices (BfArM), remind you of the pregnancy prevention program for oral retinoids. They are highly teratogenic and their use is therefore contraindicated during pregnancy. Oral retinoids are also contraindicated in women of childbearing age unless all conditions of the pregnancy prevention program (PPP) are met.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN